

Supplementary Table 2. Risk Factors of Endoscopic Postoperative Recurrence in 199 Patients Exposed to Anti-TNF Prior to Surgery (Multivariable Analysis)

Source	OR (95% CI)	P-value
Female sex	0.464 (0.237–0.908)	0.025
Active smoker	0.700 (0.258–1.902)	0.484
Perianal lesions	1.711 (0.832–2.290)	0.144
Prior bowel resection	1.194 (0.623–1.759)	0.593
Resection length > 30 cm	1.636 (0.842–3.178)	0.147
Surgery for refractoriness to medical therapy	8.390 (0.987–71.351)	0.051
Metronidazole to prevent endoscopic POR	0.546 (0.204–2.460)	0.228
Fistulizing phenotype (B3)	0.837 (0.431–1.628)	0.601
At least 3 biologics before surgery	2.676 (1.012–7.079)	0.047
Combination therapy	Reference	
Anti-TNF monotherapy	2.450 (1.099–5.482)	0.029
Conventional therapy	2.631 (1.078–6.381)	0.032
Anti-integrin therapy	1.872 (0.526–6.659)	0.333
Ustekinumab	0.218 (0.007–6.676)	0.383

TNF, tumor necrosis factor; OR, odds ratio; CI, confidence interval; POR, postoperative recurrence.